Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EMA To Decide On Comirnaty In 12-15-Year-Olds, Cuba Presses On With Homegrown Vaccine Rollout

Executive Summary

At global level, Médecins Sans Frontières has called for all countries to support a revised version of the IP waiver for COVID-19 vaccines, singling out the recalcitrant European Commission for special attention.

You may also be interested in...



EU Still Resisting COVID-19 Vaccine IP Waiver

The pharmaceutical industry and Médecins Sans Frontières have both criticized the EU’s proposals for avoiding a waiver of intellectual property rights on COVID-19 vaccines and treatments, albeit for different reasons.

EU Backs Compulsory Licensing & Production Boost For COVID-19 Vaccines

The European Commission is to present the World Health Organization with a set of proposals to tackle the barriers to the global rollout of COVID-19 vaccines. They include allowing the issue of compulsory licenses without consulting the rights holder, encouraging vaccine companies to expand production through licensing deals and contract manufacturing, and eliminating vaccine export restrictions.

Pfizer/BioNTech’s COVID-19 Vaccine Moves Into Adolescents; Adcomm To Weigh Broader Pediatric Issues

Emergency use authorization in 12-15 year-olds follows announcement of a June advisory committee meeting on pediatric data requirements, including the FDA’s criteria for younger children. Authorization for US adolescents has raised ethical questions about prioritizing this lower-risk group over hard-hit populations overseas.

Related Content

Topics

UsernamePublicRestriction

Register

PS144383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel